Abstracts tagged "complement"

Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 0144 • ACR Convergence 2022
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Guy Katz¹, Amelia S. Cogan¹, Grace McMahon¹, Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹, John Atkinson², Alfred Kim² and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
Abstract Number: 0317 • ACR Convergence 2022
Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression
Ivan Ferraz Amaro¹, maría García-González², carmen Ferrer-Moure², Fuensanta Gómez-Bernal², Antonia De Vera-González², Alejandra González Delgado², Agustín Francisco González-Rivero², Yolanda Fernández-Cladera², Juan Carlos Quevedo Abeledo³ and Federico Díaz-González⁴, ¹Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife
Background/Purpose: Activation of the classical complement (C) pathway by immune complexes is a characteristic of patients with systemic lupus erythematosus (SLE). Accelerated consumption outstrips synthesis…
Abstract Number: 0524 • ACR Convergence 2022
A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis
Peter Merkel¹, Bernhard Hellmich², Anja Pfaff³, Carina Müller⁴, Elena Startseva³ and David Jayne⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ³InflaRx, Jena, Germany, ⁴Metronomia Clinical Research, Munich, Germany, ⁵University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Induction of remission for severe ANCA-associated vasculitis [granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)] utilizes rituximab (RTX) or cyclophosphamide (CYC) and tapering doses…
Abstract Number: 0565 • ACR Convergence 2022
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics
Juan Vargas¹, Nirmal Banda², Ian Mantel³, Anna Jonsson⁴, Kevin Wei⁵, Deepak Rao⁴, Susan Goodman⁶, Kevin D Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri⁴, Accelerating Medicines Partnership RA/SLE⁴, Michael Holers², Laura Donlin⁶ and Fan Zhang⁸, ¹School Public Health Biostatistics Department, Aurora, CO, ²Department of Medicine Division of Rheumatology, Aurora, CO, ³Weill Cornell Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁸University of Colorado, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Edmund Chang¹, Julian Low², Ellen Cahir-McFarland², Henk-Andre Kroon², Yaisa Andrews-Zwilling², Ted Yednock² and Ann Mongan², ¹Annexon Biosciences, Brisbane, CA, ²Annexon Biosciences, South San Francisco, CA
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
Abstract Number: 0650 • ACR Convergence 2022
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
Shudan Wang¹, Masako Suzuki², Daming Shao³, Muhammad Hamza Bukhari⁴, Brianna Lally⁵, Michael Belmont⁶, Jennifer Aguilan², Simone Sidoli², Anna Broder⁷ and J. Michelle Kahlenberg⁸, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Norwalk Hospital/Yale University, Norkwalk, VA, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
Abstract Number: 0692 • ACR Convergence 2022
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
Naveen Kumar S K¹, Claire Hoy¹, Christine Rysenga¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Sherwin Navaz¹, Jacqueline Madison¹, Jason S Knight³ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…
Abstract Number: L14 • ACR Convergence 2021
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
David Jayne¹, Peter Merkel², Annette Bruchfeld³, Duvuru Geetha⁴, Alexandre Karras⁵, John Niles⁶ and Pirow Bekker⁷, ¹University of Cambridge, Cambridge, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Linköping University, Linköping, Sweden, ⁴Johns Hopkins University, Baltimore, MD, ⁵Hopital Europeen Georges Pompidou, Paris, France, ⁶Massachusetts General Hospital, Boston, MA, ⁷ChemoCentryx, Inc., San Carlos, CA
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Meshora Sthanithra², Christopher Toy², Anna Levesque², Lynn Fussner³, Alexa Meara³, Haikady Nagaraja², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol Langford⁷, Carol McAlear⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine Sreih¹², Kenneth Warrington¹³, Paul Monach¹⁴, Peter Merkel⁸, Brad Rovin³ and Dan Birmingham², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State university, Columbus, OH, ³Ohio State University Wexner Medical Center, Columbus, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic, Rochester, Minnesota, ¹⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
Abstract Number: 0873 • ACR Convergence 2021
Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Marcela Muñoz-Urbano¹, Julian Sanchez-Bautista², Yeison Santamaria-Alza¹, Diana C. Quintero-González³, Andres Ramirez², Adriana Lucía Vanegas-García⁴, Gloria M. Vasquez¹ and Luis Alonso Gonzalez³, ¹Rheumatology section, Universidad de Antioquia, Medellín, Colombia, ²Department of internal medicine, Universidad de Antioquia, Medellín, Colombia, ³Division of rheumatology, Universidad de Antioquia, Medellín, Colombia, ⁴Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia
Background/Purpose: Lupus enteritis (LE) is a potentially life-threatening manifestation of systemic lupus erythematosus (SLE), with an incidence ranging from 8% to 27%. Timely diagnosis is…
Abstract Number: 0955 • ACR Convergence 2021
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Vibeke Strand¹, Pirow Bekker², Huibin Yue², David R.W. Jayne³ and Peter Merkel⁴, ¹Stanford University School of Medicine, Portola Valley, CA, ²ChemoCentryx, San Carlos, CA, ³University of Cambridge, Cambridge, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…
Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: 1371 • ACR Convergence 2021
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Susan Murphy¹, Yen Chen², Mary Alore², Sheri Hicks² and Dinesh Khanna², ¹University of Michigan, Grosse Ile, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].